Compared with groups received pyrotinib or HDACs/mTOR inhibitor 1 monotherapy or vehicle, combination group had obviously stronger antitumor effect in CDXs and PDXs with significant reduction of tumor volume and weight (Fig. 5A–D, F–I). This evidence concerns the gene MTOR and neoplasm.